Who Can't Take Weight Loss Injections?

Summary: GLP-1 weight loss injections are off-limits for people with a personal or family history of medullary thyroid cancer, MEN2, pregnancy, or prior serious hypersensitivity, and require caution in pancreatitis, severe gastroparesis, severe IBD, eating disorders, severe kidney impairment, and post-bariatric patients.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

Weight loss injections are not for everyone. The FDA-approved GLP-1 and GLP-1/GIP injectables for weight loss are Wegovy (semaglutide 2.4 mg weekly), Zepbound (tirzepatide up to 15 mg weekly), and Saxenda (liraglutide 3.0 mg daily). All three carry a boxed warning for thyroid C-cell tumors. All three are contraindicated in pregnancy. And all three have a list of conditions that move them from "approved" to "use only with close monitoring" or "do not use at all" ^[1][2][3].

This page walks through the absolute contraindications first, then the conditions that require caution, then the populations that need a specific conversation with their prescriber.

The short list of absolute contraindications

If any of the following applies to you, the FDA labels for Wegovy, Zepbound, and Saxenda say do not start the drug ^[1][2][3].

The boxed warning is the FDA's strongest. It exists because rodents dosed with GLP-1 agonists developed thyroid C-cell tumors at clinically relevant exposures. Whether the same risk transfers to humans is unresolved, but the label treats it as a hard stop for anyone whose personal or family history flags them as higher risk.

Pregnancy and conception planning

The FDA labels for all three weight loss injectables list pregnancy as a contraindication ^[1][2][3]. Animal studies showed embryofetal harm at clinically relevant doses. There is no human pregnancy safety data adequate to overrule that signal.

Two practical points the labels make explicit:

• Stop the drug at least two months before trying to conceive for semaglutide. The long half-life (roughly seven days) means the drug remains in the body for weeks after the last dose. Wegovy's label specifies discontinuing at least two months prior to a planned pregnancy ^[1].
• Stop tirzepatide and liraglutide as soon as pregnancy is recognized. Their shorter half-lives (five days for tirzepatide, around 13 hours for liraglutide) mean less residual exposure, but the contraindication still applies the moment you intend to be pregnant ^[2][3].

If you become pregnant while on any of these injections, contact your prescriber the same day. Do not stop without a plan, but do not continue dosing.

Breastfeeding

The labels recommend against use while breastfeeding because of unknown infant exposure through milk and the absence of human data. There is no documented safe lactation dose. If you are breastfeeding and considering a weight loss injection, the conversation with your clinician should weigh the lack of safety data against your individual clinical picture; many providers will defer until after weaning.

Trying to conceive

Same logic as pregnancy. Stop two months before conception attempts for semaglutide, one month for tirzepatide and liraglutide, and use reliable contraception while on the drug. Tirzepatide may reduce the efficacy of oral contraceptives in the four weeks after each dose escalation due to delayed gastric emptying, so the Zepbound label recommends switching to a non-oral method or adding a barrier during that window ^[2].

Conditions that require caution, not always exclusion

The labels do not call these absolute contraindications, but they all earn a "use with caution" or "consider alternative therapy" note. Each one needs a real conversation, not a checkbox.

History of pancreatitis

Acute pancreatitis was reported in the clinical trials for all three drugs. The FDA labels warn prescribers to consider the risk in patients with prior pancreatitis and to discontinue immediately if pancreatitis is suspected ^[1][2][3]. A single episode of acute gallstone pancreatitis years ago is a different conversation than chronic recurrent pancreatitis. The drug is not formally banned, but many specialists will steer high-risk patients toward non-GLP-1 alternatives.

Symptoms to watch for once on therapy: severe, persistent abdominal pain that radiates to the back, with or without vomiting. Stop the injection and seek care the same day.

Severe gastroparesis

GLP-1 agonists work in part by slowing gastric emptying. In someone whose stomach already empties poorly, that mechanism stacks on top of an existing problem. The Wegovy and Zepbound labels caution against use in patients with severe gastroparesis because of unstudied safety ^[1][2]. Mild idiopathic delayed emptying is a different category than diabetic gastroparesis with documented retention; the latter usually disqualifies.

Severe inflammatory bowel disease

Crohn's and ulcerative colitis are not listed as formal contraindications, but the labels note that GLP-1 GI adverse effects (nausea, vomiting, diarrhea, constipation) are common and dose-dependent. In a patient with active severe IBD, those side effects can be hard to distinguish from a disease flare, and the drug's gut motility effects may complicate the picture. Most gastroenterologists prefer to wait for disease quiescence before adding a GLP-1.

Eating disorders

The Wegovy, Zepbound, and Saxenda labels note that the safety and efficacy of these drugs have not been established in patients with a history of an eating disorder, and prescribers should be cautious ^[1][2][3]. The appetite suppression that drives weight loss for most users can reinforce restrictive patterns in someone with anorexia nervosa or bulimia history. Specialist input from an eating disorder clinician is the standard of care here, not a pharmacy intake form.

Severe renal impairment with dehydration risk

GLP-1 injections frequently cause nausea, vomiting, and diarrhea, especially during titration. In a patient with eGFR below 30 mL/min, volume loss can trigger acute kidney injury. The FDA labels for all three drugs recommend monitoring renal function in patients with kidney disease and discontinuing if severe GI side effects lead to dehydration ^[1][2][3]. Dialysis-dependent patients are usually excluded outside of trial settings.

Severe hepatic impairment

Wegovy has limited data in severe hepatic impairment and the label says to use with caution ^[1]. Tirzepatide and liraglutide are similar. The cytokine and bile acid changes from GLP-1 agonism are not well characterized in advanced liver failure, and most prescribers defer to a hepatologist.

History of diabetic retinopathy

In trials of semaglutide for type 2 diabetes, rapid improvement in glucose control was associated with worsening of established diabetic retinopathy. The Wegovy label notes the finding and recommends monitoring patients with a history of diabetic retinopathy ^[1]. This is not a contraindication, but it changes how an endocrinologist titrates and how often the eye doctor sees the patient.

Suicidal ideation and depression

Post-marketing reports flagged depression and suicidal thoughts on GLP-1 weight loss drugs. The FDA reviewed the signal in 2024 and did not find a causal link sufficient to add a warning, but the Wegovy and Saxenda labels still advise monitoring for new or worsening depression or suicidal thoughts during treatment ^[1][3]. Active suicidality is not a formal contraindication, but a recent suicide attempt or active severe depression is a reason to pause the conversation.

Age limits

The age cutoffs differ by product. This is the most-confused area in patient-facing materials.

Wegovy was approved for adolescents 12 and older in December 2022 on the strength of the STEP TEEN trial, which showed a mean BMI reduction of 16.1% versus 0.6% on placebo over 68 weeks ^[5]. Saxenda earned its pediatric approval earlier on the strength of a similar trial ^[4]. Zepbound's pediatric studies are ongoing; the current label restricts it to adults 18 and older ^[2].

For children under 12, none of these drugs are approved. Off-label prescribing in this age band is rare and usually limited to specialist obesity medicine clinics with a formal research protocol.

There is no upper age limit on any of these labels. Adults in their seventies and eighties can be candidates if they meet the BMI criteria, are not frail, and can tolerate the GI side effects during titration. Older adults need closer renal monitoring and a lower threshold to stop if dehydration develops.

Bariatric surgery considerations

GLP-1 injections after bariatric surgery is a common question, and the answer depends on what surgery you had and how long ago.

• Sleeve gastrectomy and Roux-en-Y gastric bypass patients can receive GLP-1 injections. Several published case series and a growing body of clinical practice support GLP-1 use for weight regain after bariatric surgery. The injections do not interfere with the anatomy and they often work well in this population because the appetite suppression complements the restrictive component of the surgery.
• The first three to six months after surgery is generally not the right window. Patients are already losing weight rapidly, often dealing with their own GI symptoms from the surgery, and adding a GLP-1's nausea and slowed emptying on top is poorly tolerated. Most bariatric programs wait until weight loss has plateaued before adding pharmacotherapy.
• Adjustable gastric band patients can use GLP-1 injections without anatomic concern.
• Duodenal switch is the one to flag. The malabsorptive component changes drug absorption for many oral medications; the subcutaneous GLP-1 injection itself absorbs the same, but the underlying nutritional status of these patients deserves a closer look before adding any drug that further reduces intake.

The Zepbound, Wegovy, and Saxenda labels do not list bariatric surgery as a contraindication ^[1][2][3]. This is a clinical judgment call your surgeon and prescriber make together.

Cardiovascular considerations

Heart failure is not a contraindication. Semaglutide showed cardiovascular benefit in the SELECT trial of patients with established cardiovascular disease and overweight or obesity, and Wegovy now carries an FDA indication for reducing major adverse cardiovascular events in adults with established CVD and either obesity or overweight ^[1]. Tirzepatide has its own cardiovascular outcomes trial reading out in stages.

Two specific cardiac flags:

• Recent acute coronary syndrome or decompensated heart failure is a "wait until stable" situation, not a permanent ban.
• Heart rate increase of two to four beats per minute is consistent on GLP-1s. Patients with baseline tachycardia or significant arrhythmia history get a closer look.

Gallbladder issues

The FDA labels for all three drugs warn about gallbladder disease, including cholelithiasis and cholecystitis, reported during clinical trials ^[1][2][3]. Rapid weight loss of any kind raises gallstone risk; the GLP-1 effect appears to be additive.

People without a gallbladder (post-cholecystectomy) can still use GLP-1 weight loss injections. There is no contraindication. Some patients report more diarrhea or fat-intolerance symptoms in this combination, since both the absent gallbladder and the GLP-1 affect fat digestion and motility, but neither is dangerous and most adapt.

PCOS

Polycystic ovary syndrome is not a contraindication, and in fact GLP-1 injections are increasingly used off-label in women with PCOS and obesity. Weight loss improves insulin resistance, ovulatory function, and androgen levels in PCOS. None of these drugs carry an FDA indication for PCOS, so use is off-label, and the same boxed warning and pregnancy contraindication apply. PCOS patients trying to conceive should follow the same wash-out windows above.

Drug interactions worth flagging

The labels do not call these contraindications, but they earn a conversation:

• Insulin and sulfonylureas: hypoglycemia risk rises when GLP-1 injections are added. Dose reductions are routine.
• Warfarin and other narrow-therapeutic-index oral drugs: delayed gastric emptying changes absorption timing. INR monitoring frequency goes up during titration.
• Oral contraceptives with Zepbound: efficacy may drop in the four weeks after each dose escalation; switch to a non-oral method or add a barrier ^[2].

Quick decision guide

Common questions

Who cannot take weight loss injections under any circumstances?

Anyone with a personal or family history of medullary thyroid carcinoma or MEN2, anyone who had a serious hypersensitivity reaction to a prior dose, anyone currently pregnant, and children under age 12.

Who shouldn't take weight loss injections without specialist input?

People with prior pancreatitis, severe gastroparesis, severe IBD, active eating disorders, severe renal or hepatic impairment, a history of diabetic retinopathy, or active severe depression with suicidal ideation.

What is the age limit for weight loss injections?

Wegovy and Saxenda are approved from age 12. Zepbound is adults only (18+). No upper age limit applies to any of these drugs, but frailty and renal function guide dosing in older adults.

Can you take weight loss injections when pregnant?

No. Pregnancy is a contraindication on every FDA label. Animal studies showed embryofetal harm. Stop the drug as soon as pregnancy is recognized and contact your prescriber.

Can you take weight loss injections while trying to conceive?

Stop semaglutide (Wegovy) at least two months before conception attempts. Stop tirzepatide and liraglutide at least one month before. Use reliable contraception while on therapy.

Can I take weight loss injections while breastfeeding?

The labels recommend against it because infant exposure through milk is unknown and there is no human safety data. Most prescribers defer until after weaning.

Can you have weight loss injections without a gallbladder?

Yes. There is no contraindication after cholecystectomy. Some patients notice more diarrhea since both the missing gallbladder and the GLP-1 affect fat digestion, but it is not dangerous.

Can you have weight loss injections with heart failure?

Stable heart failure is not a contraindication. Semaglutide showed cardiovascular benefit in SELECT and Wegovy is now FDA-indicated for cardiovascular risk reduction in eligible patients. Wait until decompensated heart failure stabilizes before starting.

Can you have weight loss injections after bariatric surgery?

Yes, once the early post-op period is past (typically three to six months) and weight loss has plateaued. Sleeve, bypass, and band patients all use GLP-1s for weight regain. Duodenal switch patients need closer nutritional review.

Can weight loss injections help with PCOS?

Yes, off-label. Weight loss improves insulin resistance, ovulation, and androgen levels in PCOS. The boxed warning and pregnancy contraindication still apply. Stop the drug before conception attempts.

Does a family history of any thyroid cancer disqualify me?

Only medullary thyroid carcinoma triggers the boxed warning. Papillary, follicular, and anaplastic thyroid cancers are different cell types and do not carry the same C-cell signal. A clear MTC history in a first-degree relative is the disqualifier.

Can I switch from Wegovy to Zepbound if one is contraindicated?

The boxed warning and the pregnancy contraindication apply equally to both. Hypersensitivity is drug-specific, so a reaction to one does not automatically rule out the other, but specialist input is required. Gastroparesis, IBD, and renal cautions also apply to both classes.